VITRAFY LIFE SCIENCES LIMITED (VFY)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

VFY - VITRAFY LIFE SCIENCES LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -0.02
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.30

05 May
2026

0.020

OPEN

$2.32

0.88%

HIGH

$2.35

125,007

LOW

$2.28

TARGET
$2.70 17.4% upside
FNARENA'S MARKET CONSENSUS FORECASTS
VFY: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 51.2 - 21.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 20242025
EPS Basic xxx-51.2
DPS All xxx0.0
Sales/Revenue xxx0.1 M
Book Value Per Share xxx45.1
Net Operating Cash Flow xxx-8.8 M
Net Profit Margin xxx-50,237.25 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20242025
Return on Capital Employed xxx-1,570.08 %
Return on Invested Capital xxx-1,345.65 %
Return on Assets xxx-157.19 %
Return on Equity xxx-1,570.08 %
Return on Total Capital xxx-118.28 %
Free Cash Flow ex dividends xxx-8.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20242025
Short-Term Debt xxx0 M
Long Term Debt xxx0 M
Total Debt xxx0 M
Goodwill - Gross xxx-
Cash & Equivalents - Generic xxx30 M
Price To Book Value xxx3.33

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20242025
Capex xxx0.0 M
Capex % of Sales xxx2.85 %
Cost of Goods Sold xxx1 M
Selling, General & Admin. Exp & Other xxx16 M
Research & Development xxx7 M
Investments - Total xxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

24/03/2026

1

Speculative Buy

$2.40

4.35%

Ord Minnett highlights Australian Healthcare as a defensive sector amid volatile global conditions, identifying Regis Healthcare, Integral Diagnostics, Sigma Healthcare and EchoIQ as preferred exposures.

Earnings resilience and multiple growth drivers support the sector, assess the analysts, particularly for companies with strong balance sheets and catalyst pipelines.

The broker notes higher bond yields have driven valuation resets, with weighted average cost of capital (WACC) assumptions lifted and target prices reduced across research coverage.

Cost pressures, the analysts note, are most evident for wholesalers and pathology providers given freight exposure and limited near-term pricing power.

Ord Minnett retains a Speculative Buy rating for Vitrafy Life Sciences and lowers its target to $2.40 from $2.50.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents.
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

VFY STOCK CHART

FNArena News on VFY

1
FNArena Corporate Results Monitor – 05-02-2026

Feb 05 2026 - Australia
2
FNArena Corporate Results Monitor – 06-08-2025

Aug 06 2025 - Australia
3
FNArena Corporate Results Monitor – 07-02-2025

Feb 07 2025 - Australia